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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.12.052Objective: The heart possesses an extraordinary ability to remember short episodes
of sublethal ischemia and reperfusion (angina), which protects the myocardium and
coronary vasculature from a subsequent lethal insult, a phenomenon known as
ischemic preconditioning. A therapeutic goal for more than 2 decades has been to
develop a pharmacologic mimetic comparable with ischemic preconditioning. Our
aim was to investigate the preconditioning effect of a new combinatorial therapy
targeting adenosine A1 receptors and voltage-dependent sodium fast channels in the
in vivo rat model of regional ischemia.
Methods: Ischemia-reperfusion was achieved by placing a reversible tie around the
left coronary artery in anesthetized and ventilated Sprague-Dawley rats (n  37).
Rats were randomly assigned to 1 of 5 groups: (1) saline control (n  13); (2)
ischemic preconditioning (n  6); (3) lidocaine only (608 g · kg1 · min1, n 
5); (4) adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA; 5
g/kg, n  7); and (5) CCPA plus lidocaine (n  6). Ischemic preconditioning was
achieved by using 3 cycles of ischemia and reperfusion lasting 3 minutes each.
Lidocaine was infused continuously 5 minutes before and throughout 30 minutes of
ischemia and ceased at reperfusion. A bolus of CCPA was infused 5 minutes before
ligation along with a constant infusion of lidocaine (as above). All animals were
reperfused for 120 minutes for infarct size measurement.
Results: Fifty-four percent of saline control rats, 17% of ischemic preconditioning–
treated rats, and 29% of CCPA-treated rats died during ischemia from ventricular
fibrillation. Infarct size of saline control animals was 61%  5%. Pretreating with
CCPA and lidocaine infusion resulted in no deaths, no severe arrhythmias, and
significant infarct size reduction compared with that seen in saline control animals
(P  .05). Remarkably, infarct size reduction in CCPA plus lidocaine–treated rats
(12%  4%) was equivalent to that achieved with ischemic preconditioning (11% 
3%), whereas infarct size in rats undergoing CCPA-only and lidocaine-only treat-
ments was 42% 7% and 60% 6%, respectively. Although CCPA plus lidocaine
treatment reduced heart rate, mean arterial pressure, and systolic pressure during
ischemia, no correlation was found between these variables and infarct size reduc-
tion.
Conclusion: We conclude that activating adenosine A1 receptor subtype with CCPA
and concomitantly modulating sodium fast channels with lidocaine was comparable
with ischemic preconditioning and might offer a new therapeutic window to min-
imize myocardial damage during surgical ischemia and reperfusion.
Ischemic preconditioning (IPC) was first described in 1986 by Murry andcolleagues,1 who reported an infarct size reduction from 29% to 7% in anes-thetized open-chest dogs after 3 brief episodes of ischemia and reperfusion and
40 minutes of coronary artery occlusion. Two different time frames of precondi-
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CSPtioning have been identified: an early classical window that
lasts 1 to 3 hours after the stimulus and a delayed window
that develops over many hours and can last up to 12 to 72
hours.2-5 In addition, more recently, Zhao and associates6
have reported similar infarct-reducing effects by postcondi-
tioning the heart a few seconds after reperfusion has com-
menced.
Given the reluctance of most surgeons and clinicians to
precondition an organ in the clinical setting, the ultimate
therapeutic goal has been to develop a pharmacologic mi-
metic of IPC.7 Potential triggers include adenosine, opioids,
acetylcholine, bradykinin, catecholamines, free radicals,
and nitric oxide.4,8-12 Adenosine, an endogenous nucleo-
side, is of particular interest because in addition to trigger-
ing early and delayed IPC,5 it protects against cellular injury
at multiple sites and levels during ischemia and reperfu-
sion.13 Adenosine elicits negative chronotropic and dromo-
tropic effects,14,15 induces coronary vasodilation, and atten-
uates the inflammatory response and possibly anticlotting
processes.16-19 Four known adenosine receptor subtypes
(A1, A2a, A2b, and A3) mediate the pleiotropic effects of
adenosine, and these receptors are coupled to a wide range
of second messenger cascades.16 In the heart the adenosine
A1 receptor subtype is known to confer protection through
inhibitory G protein–coupled pathways, which has been
linked to the opening of sarcolemmal adenosine triphos-
phate (ATP)–sensitive potassium channels, increased potas-
sium conductance, action potential shortening, and reduced
Ca2 entry into ischemic cells.20 More recently, the aden-
osine A1 receptor trigger has been linked to new targets,
including the mitochondria21 and sarcoplasmic reticulum.22
Unlike adenosine A1 (and A3) receptors, cardiac Na chan-
nels have received surprisingly little attention in the precon-
ditioning or pretreatment phenomenon, despite voltage-
gated Na channels being important determinants of the cell
membrane potential, which is naturally modified toward a
more depolarized state during early ischemia.23,24
The aim of this study is to examine the effect of coad-
ministering the A1 agonist 2-chloro-N6-cyclopentyladen-
osine (CCPA) and the voltage-dependent sodium channel
modulator lidocaine during acute regional ischemia in the in
vivo rat model. Our previous work has shown that a con-
stant intravenous infusion of an adenosine-lidocaine solu-
tion administered 5 minutes before and 30 minutes during
ischemia protects against death and severe ventricular ar-
rhythmias and reduces infarct size by 40% in the rat in
vivo.25 Because A1 receptor activation has been shown to
be highly cardioprotective,16,26 we hypothesized that sub-
stituting the A1 receptor agonist CCPA for adenosine might
demonstrate greater efficacy than administering the adeno-
sine and lidocaine (AL) solution. We report that coadmin-
istering CCPA plus lidocaine before and during ischemia
completely avoided death, abolished severe arrhythmias,
372 The Journal of Thoracic and Cardiovascular Surgery ● Auguand profoundly reduced infarct size akin to that seen with
IPC. The pharmacologic activation of the adenosine A1
receptor subtype and modulation of Na fast channels
might offer an alternative to IPC for reduction of myocar-
dial damage during ischemia and reperfusion.
Materials and Methods
Animals and Reagents
Male Sprague-Dawley rats (330-400 g, fed) were anesthetized with
sodium pentabarbitone (60 mg/kg administered intraperitoneally),
which was administered as required throughout the experiment
(ethics approval no. A557). The investigation conforms with the
“Guide for Care and Use of Laboratory Animals” published by the
US National Institutes of Health (publication no. 85-23, revised
1996). Adenosine, copper II pthalocyanine-tetrasulfonic acid tet-
rasodium salt (blue dye), triphenyltetrazolium chloride (TTC), and
CCPA were obtained from Sigma Aldrich. CCPA has a 10,000-
fold sensitivity for adenosine A1 than A2 receptor and a subnano-
molar receptor affinity.5 CCPA also has a moderately potent an-
tagonistic effect (Ki  38 nmol/L) on human adenosine A3
receptor.27 Lidocaine hydrochloride was purchased as a 2% solu-
tion (ilium).
Surgical Protocol
The surgical procedure has been described by Canyon and Dobson.25
In brief, a tracheotomy was performed, and rats were ventilated at
75 to 80 strokes per minute by with a Harvard Small Animal
Ventilator. Blood PO2, PCO2, and pH were assessed (Ciba-Corning
865 blood gas analyzer). Body temperature was maintained at
37°C by using a homeothermic blanket control unit. The right and
left femoral veins and arteries were cannulated for drug infusions,
blood collection, and blood pressure monitoring (UFI 1050 BP) by
using a MacLab system (ADInstruments Pty Ltd). A left thoracot-
omy was performed through the fourth and fifth intercostal spaces.
The heart was gently exteriorized to allow for a 6-0 suture to be
threaded under the left coronary artery to a reversible snare oc-
cluder. Lead II electrocardiographic leads were implanted subcu-
taneously. Ischemia was confirmed by means of regional cyanosis
and swelling downstream of the occlusion, and reperfusion was
confirmed by lack of cyanosis and reduced swelling in that region.
Any animal with dysrhythmias or a sustained decrease in mean
arterial blood pressure of less than 80 mm Hg before ischemia was
not included.25
Experimental Design
Rats (n  37) were randomly assigned to one of 5 groups: (1)
saline (0.9%) control (n  13); (2) IPC (n  6); (3) lidocaine only
(608 g · kg1 · min1, n  5); (4) CCPA (5 g/kg, n  7); and
(5) CCPA plus lidocaine (n  6). IPC was achieved before
coronary artery occlusion with 3 cycles of ischemia and reperfu-
sion, with each transition lasting 3 minutes. Lidocaine was infused
continuously 5 minutes before and throughout 30 minutes of
regional ischemia and ceased at reperfusion. A bolus of CCPA was
infused 5 minutes before ligation alongside a continuous infusion
of lidocaine, which was continued during 30 minutes ischemia. All
animals were reperfused for 120 minutes for infarct size measure-
ment. The primary end points were death, episodes and duration of
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Pventricular arrhythmias, and infarct size. Infarct size reduction is
considered one of the gold standard measures of IPC.3 Hemody-
namics were collected throughout the study and constituted the
secondary end points: heart rate, systolic pressure, mean arterial
pressure (MAP; Systolic pressure  Diastolic pressure/3  Dia-
stolic pressure), and rate-pressure product (RPP; Heart rate 
Peak systolic pressure).
Arrhythmia Analysis
Arrhythmias were analyzed during ischemia and the first 30 min-
utes of reperfusion. By using the lead II electrocardiographic
tracing, the episodes and duration of episodes of ventricular fibril-
lation (VF) and ventricular tachycardia (VT) were recorded. VF
was defined as a signal in which individual QRS deflections could
not easily be distinguished from each other and n which rate could
no longer be measured, and VT was defined as 4 or more consec-
utive ventricular premature beats.28
Analysis of the Ischemic Area at Risk and Infarct Size
After 120 minutes of reperfusion, the coronary artery was reoc-
cluded, and the heart was excised. Blue dye (3 mL) was flushed
retrograde through the aorta and allowed to circulate through the
coronary vasculature to delineate the ischemic risk zone. The heart
was sliced transversely into 6 or 7 slices of uniform thickness (2
mm).25 The slices were weighed and digitally photographed for
area measurements. The area left unstained by the blue dye was
defined as the left ventricular area at risk (AAR/LV), and the
blue-stained region was the perfused area. The slices were then
incubated in a 1% solution of TTC at 37°C for 15 minutes,29
immersed in formalin, and photographed again. The area of ne-
crosis in the left ventricle (AN/LV) was the region of the slice
unstained by TTC (white), and the noninfarcted region was the
area of the slice stained by TTC (brick red). Infarct size was
defined as the ratio of the area of necrosis to the area at risk
(AN/AAR) and expressed as a percentage.25
Statistical Analysis
All values were expressed as means SE of the mean. Infarct size
and hemodynamic data were evaluated by using 1-way analysis of
variance with a Tukey honestly significant difference post-hoc test.
A Mann-Whitney U test was used for comparison of arrhythmia
frequency and duration because the variables of VT and VF are not
normally distributed. The relationship between RPP and infarct
size was examined with the Pearson correlation coefficient.
Results
Death during ischemia from ventricular arrhythmias oc-
curred in 54% of saline control animals (7/13 died), 17% of
IPC-treated rats (1/6 died), and 29% of CCPA-treated rats
(2/7 died). None of the lidocaine-treated rats (n  5) or
CCPA plus lidocaine–treated rats (n  6) died. Only data
from surviving rats were further analyzed.
Ischemia-induced ventricular arrhythmias are shown in
Figure 1. During ischemia, the saline control group experi-
enced 130  64 seconds of ventricular arrhythmia (VT, 89
 41 seconds; VF, 41  26 seconds), whereas CCPA-
treated animals tolerated 56 18 seconds of VT and no VF.
The Journal of ThoraciForty percent of the IPC-treated rats experienced 4  3
episodes of VT for 8  6 seconds. Within the lidocaine
group, 100% experienced VT (28  13 episodes, 38  20
seconds), and 40% experienced VF (2  2 episodes, 7  5
seconds). Treatment with CCPA plus lidocaine completely
abolished VT and VF (Figure 1). Immediately after isch-
emia, 80% of saline control rats, 60% of IPC-treated rats,
100% of CCPA-treated, and 20% of lidocaine-treated rats
experienced reperfusion tachycardias. No ventricular ar-
rhythmias during reperfusion were experienced in rats pre-
treated with CCPA plus lidocaine.
The mean AAR/LV, AN/LV, and AN/AAR are shown in
Figure 2. The areas at risk expressed as a percentage of the
left ventricle were not significantly different among the 5
groups and on average comprised 60%  3%. The areas of
necrosis in saline control rats, IPC-treated rats, CCPA-
treated rats, lidocaine-treated rates, and CCPA plus lidocaine–
treated rats were 31%  2%, 7%  2%, 24%  3%, 35%
Figure 1. The episodes and duration of VT and VF and VT plus VF
during ischemia for surviving rats in all treatment groups. These
values represent the overall sum of episodes and durations (in
seconds) that occurred throughout the 30-minute ischemic period.
Surviving rats: control, n  6; IPC, n  5; A1 agonist only (CCPA),
n  5; lidocaine only (LIDO), n  5; A1 agonist plus lidocaine
(CCPALIDO), n  6. Data are presented as means  SEM. *P <
.05 versus control animals. †P < .05 versus IPC-treated animals. 4%, and 8%  3%, respectively. The mean infarct size
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CSPwas 61  5% for saline controls rats, 11%  3% for
IPC-treated rats, 42% 7% for CCPA-treated rates, 60%
6% for lidocaine-treated rates, and 12%  4% for CCPA
plus lidocaine–treated rats (Figure 2). IPC and pharmaco-
logic pretreating with CCPA plus lidocaine were both sig-
nificantly reduced compared with that seen in control ani-
mals (P .05) but were not significantly different from one
another.
The hemodynamic changes during pretreatment, isch-
emia, and reperfusion are shown in Table 1. For each
treatment, MAP was lower during ischemia and signifi-
cantly lower at 120 minutes of reperfusion compared with
baseline values. MAPs in IPC-treated, CCPA-treated,
lidocaine-treated, and CCPA plus lidocaine–treated rats
were also lower before occlusion compared with their re-
spective baseline values. Rats pretreated with CCPA plus
lidocaine also experienced significant reductions in heart
rate, MAP, and systolic pressure compared with values
Figure 2. Effects of IPC, CCPA, lidocaine (LIDO), and CCPA plus
lidocaine on left ventricular necrosis and infarct size. A, Areas at
risk (AAR/LV, clear bars) were not significantly different between
groups. Areas of necrosis in the left ventricle (AN/LV, filled bars)
were significantly smaller with IPC and CCPA plus lidocaine
treatment. B, Infarct sizes (AN/AAR) in groups receiving IPC and
CCPA plus lidocaine treatment were significantly smaller com-
pared with those of all other treatment groups. Surviving rats:
control, n  6; IPC, n  5; A1 agonist only (CCPA), n  5;
lidocaine only (LIDO), n  5; A1 agonist plus lidocaine
(CCPALIDO), n  6. Data are means  SEM. *P < .05 versus
control animals.observed in saline control rats and IPC-treated rats. Al-
374 The Journal of Thoracic and Cardiovascular Surgery ● Auguthough hemodynamic measurements were lower than base-
line values after 2 hours of reperfusion in all groups, no
group was significantly different from another, with the
exception of those receiving only lidocaine. The Pearson
correlation coefficient was analyzed for time points before
the reperfusion period to assess whether changes in RPP
influenced the final infarct size measurements. No signifi-
cant correlations were found for any of the treatment groups
tested, including control rats and IPC-treated rats.
Discussion
A goal for more than 2 decades has been to develop a
pharmacologic mimetic of IPC to protect the heart during
acute regional ischemia. Nearly every IPC study has shown
a profound reduction in infarct size, and most have reported
a large reduction in arrhythmias. However, some studies,
including the original study of Murry and colleagues,1,30
have reported a proarrhythmic effect of IPC, which might
predispose the heart to stunning.31,32 Our report shows that
coadministration of the A1 receptor agonist CCPA and the
Na fast-channel modulator lidocaine 5 minutes before and
during 30 minutes of regional ischemia led to no deaths, no
life-threatening arrhythmias, and a profound reduction in
myocardial infarct size. Remarkably, the reduction of in-
farct size from 61% to 12% was equivalent to that achieved
with IPC (Figure 2). Moreover, the combination of CCPA
and lidocaine surpassed IPC protection by virtually abolish-
ing ventricular arrhythmias and resulting in no deaths (Fig-
ure 1).
Previously, we have shown that constant infusion of AL
had similar effects to CCPA and lidocaine but differed in
the degree of infarct size reduction compared with that seen
in saline control animals.25 Substituting the A1 agonist
CCPA for adenosine reduced infarct size from 38% (AL) to
12%. Thus we have shown that both ischemia therapies
confer significant advantages to collectively protect against
mortality, severe arrhythmias, and cell death compared with
that seen in saline control rats, adenosine-treated rats,
lidocaine-treated rats, or CCPA-treated rats (Figures 1 and
2).25 With the exception of lidocaine treatment, 29% of
CCPA-treated rats and 50% of adenosine-treated rats died
during ischemia (Figures 1 and 2).25 It was only the com-
bination of CCPA plus lidocaine or AL solution that con-
ferred an overall survival benefit, virtual abolition of severe
arrhythmias, and reduction in infarct size. As mentioned in
our earlier study with AL solution,25 the current protocol is
very different from that of Homeister and associates,33 who
administered an intravenous bolus of lidocaine in open-
chest dogs 1 minute before a 90-minute occlusion of the left
circumflex coronary artery and again 1 minute before reper-
fusion, immediately followed by adenosine infusion at
reperfusion and continued for 1 hour. In our studies CCPA
plus lidocaine or AL was administered simultaneously 5
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Pminutes before and during 30 minutes of regional ischemia
and not separately and sequentially.
In an effort to understand how CCPA plus lidocaine (or
AL solution) confers its cardioprotective effects, it is im-
portant to separate the direct effects of pretreatment on
infarct size reduction and the indirect effects caused by
hemodynamic changes. Hypotension, for example, might
indirectly reduce infarct size by lowering left ventricular
work. To tease apart this complex question, let us assume
for a moment that the entire infarct size reduction from
saline control animals (61%) to AL-treated rats (38%) re-
ported by Canyon and Dobson25 was caused by hypoten-
sion. Because MAP was not significantly different between
AL treatment (baseline, 125 11 mm Hg; before occlusion,
45  4 mm Hg; 25 minutes of ischemia, 49  5 mm Hg;
and 120 minutes of reperfusion, 86  6 mm Hg)25 and
CCPA plus lidocaine treatment (baseline, 110 12 mm Hg;
before occlusion, 49  4 mm Hg; 30 minutes of ischemia,
44 2 mm Hg; and 120 minutes of reperfusion, 72 5 mm
Hg; Table 1), the contribution of hypotension to infarct size
reduction in CCPA plus lidocaine–treated rats could not
exceed the decrease from 61% to 38% (ie for AL treatment).
Thus the maximal contribution of hypotension to infarct
size reduction from 61% to 12% in CCPA plus lidocaine–
treated rats would be 61  38⁄61  12100  47%,
with the remaining 53% reduction coming directly from the
pharmacologic therapy itself. Of course, if our assumption
that infarct size reduction in AL-treated rats (61% to 38%)
was not caused by hypotension, then the direct effect of
TABLE 1. Hemodynamic parameters before and during is
before ischemia (before occlusion)
Treatment Parameter Bas
Saline control HR (beats/min) 450
MAP (mm Hg) 115
Systolic blood pressure (mm Hg) 143
IPC HR (beats/min) 438
MAP (mm Hg) 130
Systolic blood pressure (mm Hg) 163
CCPA HR (beats/min) 421
MAP (mm Hg) 114
Systolic blood pressure (mm Hg) 146
LIDO HR (beats/min) 440
MAP (mm Hg) 120
Systolic blood pressure (mm Hg) 150
CCPA  LIDO HR (beats/min) 436
MAP (mm Hg) 110
Systolic blood pressure (mm Hg) 131
Data are presented as means  SEM. Surviving rats: saline control, n 
lidocaine only, n 5; CCPALIDO, A1 agonist plus lidocaine, n 6. HR, He
IPC.CCPA plus lidocaine infusion on infarct size reduction
The Journal of Thoracicould conceivably approach 100%. This suggestion is con-
sistent with Casati and associates,34 who showed that the
protective action of CCPA activation of A1 receptors in the
in vivo rabbit model, which was independent of changes to
hemodynamics, including MAP. De Jonge and colleagues9
have also shown in the isolated rat heart that the bradycardia
effect of CCPA (Table 1) contributes little to infarct size
reduction in the paced and nonpaced heart. More recently,
Peart and Gross35 have ruled out the possibility of CCPA’s
bradycardic effect influencing infarct size reduction in
paced rat hearts in vivo. Similarly, when RPP, an index of
myocardial oxygen consumption, is plotted against infarct
size, we found no significant correlations for CCPA or
CCPA plus lidocaine–treated animals. However, for the
lidocaine-only treatment, RPP at the end of the reperfusion
period (120 minutes) was positively correlated with increas-
ing infarct sizes; a higher RPP at 120 minutes led to a higher
infarct size (r0.90, P .05) but not at any other times.
The underlying mechanisms for the cardioprotective effects
of coadministering CCPA plus lidocaine (or AL solution)
during ischemia are not currently known but are likely to occur
at 3 integrated levels: electrophysiologic, mechanical, and met-
abolic. Electrophysiologically, the near-complete abolition of
ventricular arrhythmias (Figure 1) might be linked to adeno-
sine A1 receptor and lidocaine’s ability to improve atrioven-
tricular matching of conduction and pump performance. It is
well known that adenosine, by activating A1 receptors, slows
the sinoatrial nodal pacemaker rate, delays atrioventricular
nodal impulse conduction, and reduces atrial contractility.36
mia and reperfusion and immediately after pretreatment
Before occlusion 30 min of ischemia
120 min of
reperfusion
453  19 416  33 388  24
118  7 88  13 75  8
144  7 106  6 103  10
416  16 414  7 379  8
90  19 92  14 69  6
116  22 116  14 98  6
336  29* 382 4 367  12
89  10 91  10 71  2
113  11 113  12 94  4
382  17 305  27*† 393  4
87  12 57  5 71  7
115  12 83 7 99  93
270  14*† 172 26*† 347  17
49  4* 44  2*† 72  5
77  7* 59  3*† 97  9
C, ischemic preconditioning n  5; CCPA, A1 agonist only, n  5; LIDO,
te; MAP, mean arterial pressure. *P .05 versus control. †P .05 versusche
eline
17
5
6
9
8
12
15
6
6
19
10
10
18
12
9
6; IP
art raAdenosine’s net effect appears greatest at the atrioventricular
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CSPnode, where it is 30 times more effective in slowing conduc-
tion than sinoatrial pacemakers, which at therapeutic concen-
trations might reduce re-entry arrhythmias.37 Indeed, adeno-
sine is chiefly used by clinicians to abate narrow complex
supraventricular tachycardia but can also assist, to a lesser
degree, in the management of VT of aberrant origin.37 As an
antiarrhythmic, adenosine A1 agonist activation also inhibits
the effect of catecholamines by reducing cyclic adenosine
monophosphate and slowing Ca2 influx36 and has been im-
plicated in opening myocardial ATP-sensitive potassium chan-
nels,12,20,38 which might further stabilize the resting mem-
brane potential and conduction inhomogeneities during
contraction and relaxation. One or more of these actions
might also be enhanced by lidocaine’s effects on sodium
channels and therefore excitability, which is potentiated in
ventricular tissue by ischemic conditions.39 Lidocaine at
low concentrations reduces voltage-dependent Na entry
and effectively resets the membrane potential to a more
polarized voltage (ie, limit the reduction in ischemic-
induced maximum diastolic potential)40 and, like adenosine,
can shorten the action potential and thereby reduce Ca2
entry into the cell.36 The overall effect could be to down-
regulate myocardial metabolism during ischemia and
thereby improve pump performance in the postischemic
period. Thus reduction of atrial and ventricular myocyte
excitability, possible shortening of the action potential, and
slowing of repolarization might explain how the combina-
tion of adenosine A1 receptor activation and lidocaine abol-
ishes ventricular arrhythmias in the rat model and leads to a
better electrical and metabolic matching in both ischemic
and nonischemic regions of the heart. To this end, we have
recently shown that 31P nuclear magnetic resonance–
derived myocardial ATP levels are extremely stable during
acute regional ischemia compared with ATP in the hearts of
saline control animals, indicating an improved steady-state
matching between supply and demand (work in progress).
In conclusion, we demonstrate a multitiered benefit of
coadministering CCPA plus lidocaine before and during
regional ischemia in the rat in vivo. At higher concentra-
tions, the combination could also be used as a nondepolar-
izing surgical cardioplegia, as we have recently reported for
AL.14,15 In addition, novel adenosine agonists, allosteric
modifiers, or both or different pharmacologic mixtures of
A1, A2, and A3 agonists and perhaps selective antagonists
could be used with Na channel modulation to protect and
preserve organs and tissues in a number of clinical and
surgical settings, including organ transplantation.
Limitations to the Study Protocol
A possible limitation of using intravenous infusions of A1
agonist plus lidocaine (or adenosine plus lidocaine) in the
clinical setting might be the combination’s effect on hemo-
dynamics before occlusion and during regional ischemia (ie,
376 The Journal of Thoracic and Cardiovascular Surgery ● Augudecreased heart rate, MAP, or systolic pressure). Where
acute systemic hypotension is to be avoided,7,17 adenosine
A1 receptor activation plus lidocaine (or AL) therapy
could be administered through an intracoronary route and
used for percutaneous coronary interventions, off- and
on-pump heart surgery, and perioperative applications, or
alternatively, intravenous infusions could be considered
at lower concentrations of one or both of the drugs in
combination. Further studies are required to determine
the appropriate dose-response curves in larger animals
before clinical testing.
We thank Professor Jakob Vinten-Johansen and Professor
Emeritus Arnold Katz for their helpful discussions on parts of the
manuscript.
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